All conditions

Vitiligo

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

299
Trials on record
34
Recruiting now
2
Australian sites
5
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Vitiligo →

Get alerts when Vitiligo trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Vitiligo

Vitiligo is a condition where the skin loses its natural colour in patches. This happens because the cells responsible for producing skin pigment, called melanocytes, stop working or are destroyed. The result is lighter or white patches that can appear anywhere on the body, including the face, hands, and areas around body openings. The patches can vary greatly in size and may grow or spread over time, though this is unpredictable and differs from person to person. Vitiligo is not contagious, and it is not caused by anything the affected person did or did not do.

In Australia, vitiligo affects people of all ages, backgrounds, and skin types, though it is often more noticeable on darker skin tones. It is estimated to affect around one to two percent of the population, meaning hundreds of thousands of Australians are living with this condition. It can develop at any age, but many people first notice it before the age of 30. While vitiligo is not physically painful and does not affect overall physical health, it can have a significant emotional and social impact, and these feelings are completely valid and widely recognised by healthcare professionals.

Treatment for vitiligo focuses on either restoring colour to the affected patches or evening out the skin tone more broadly. Options that doctors commonly discuss include light-based therapies, topical creams applied to the skin, and in some cases oral or injectable medications. Some people also explore cosmetic approaches such as camouflage products. Not every treatment works for everyone, and results can take time. A dermatologist is usually the specialist best placed to assess the individual situation and explain which options may be worth considering.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Vitiligo in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Vitiligo currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Vitiligo.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Vitiligo by country. Australia is highlighted.

Showing the top 10 of 40 countries with trial sites.

Clinical trials for Vitiligo

Showing 36 of 36 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT03715829 · Pfizer Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 5 February 2021
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇪 DE🇮🇹 IT🇯🇵 JP🇰🇷 KR🇪🇸 ES +2 more

Who might be able to join this trial: - You are between 18 and 65 years old (inclusive) at the time you agree to take part - You have been diagnosed with moderate to severe active non-segmental vitiligo (a type of vitiligo that appears in patches on both sides of the body) Who may not be able to join: - You have a his...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06905873 · Forte Biosciences, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇦🇺 AU🇳🇿 NZ

**Who might be able to join this trial:** - Adults between 18 and 75 years old (at the time of the screening appointment) - People who have been confirmed by the study doctor to have non-segmental vitiligo (a type of vitiligo that appears in patches on both sides of the body) at both the screening and baseline visits -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07431177 · Novartis Pharmaceuticals Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 6 June 2028
🇦🇺 AU🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇳 IN🇮🇹 IT🇯🇵 JP +3 more

**Who might be able to join this trial:** - You must be willing and able to sign a consent form before taking part in the study - You must be 18 years of age or older (male or female as assigned at birth) at the time of your screening visit - You must have been diagnosed with non-segmental vitiligo (a specific type of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06113328 · Merck Sharp & Dohme LLC Phase 2 · 18 countries Terminated
Terminated Phase 2 Est. completion 20 March 2025
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇴 CO🇫🇷 FR🇩🇪 DE +10 more

**Who might be able to join this trial:** - You have been diagnosed with non-segmental vitiligo (the most common type, where patches appear on both sides of the body) - You have had non-segmental vitiligo for at least 6 months - The loss of skin color on your face meets a minimum level of severity based on a standard s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03577327 · Northwestern University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have vitiligo, whether or not their white patches have been spreading over the past year - People who do not have vitiligo but are a similar age and sex to those who do (these would be comparison participants) - People who are between 18 and 89 years old at the time of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03646955 · Danish Breast Cancer Cooperative Group Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2033
🇨🇱 CL🇩🇰 DK🇳🇴 NO🇸🇪 SE

**Who might be able to join this trial:** - You are a woman aged 60 or older - Your breast cancer is in one breast only and in one single area (not spread across multiple spots) - Your cancer is not the lobular type, and is graded as grade 1 or 2 (meaning it is slow to moderately growing) - The tumour measures no more...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05536856 · Al-Azhar University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2025
🇪🇬 EG

**Who might be able to join this trial:** - You have been diagnosed with localized, stable vitiligo (a skin condition causing patches of lost skin color that is not spreading). - You are older than 10 years of age. - Your vitiligo patches have not changed or spread for at least 1 year. - You have not received any treat...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06454461 · Jilin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are able to read and sign a consent form agreeing to take part in the study. - You are between 18 and 60 years old (men and women are both eligible). - You have been diagnosed with non-segmental vitiligo (the type that can appear on both sides of the body, rather than on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06548360 · Incyte Corporation Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 10 August 2026
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of vitiligo called "nonsegmental vitiligo," with patches covering at least 0.5% of your face and at least 3% of other parts of your body. - The total area of vitiligo on your body does not cover more than 10% of your skin. - You ha...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06719024 · Hospital Authority, Hong Kong Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 16 June 2025
Hong Kong

**Who might be able to join this trial:** - You are between 18 and 85 years old - You have been diagnosed with stable, non-segmental vitiligo (a type that does not involve nerve-related patches) - Your vitiligo affects at least 0.5% of your body surface area on your face and neck - You have used a prescription cream ca...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06768840 · South Valley University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2025
🇪🇬 EG

**Who might be able to join this trial:** - You have active generalized vitiligo (white patches spread across the body) that covers more than 5% of your body surface area, not counting the hands and feet - You have not taken any oral or injected vitiligo treatments in the last 3 months, and have not used any skin cream...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06801821 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years of age or older (any gender) - You must be willing and able to sign a written consent form to participate Who may not be able to join: - You cannot join if you have been diagnosed with psoriasis, atopic dermatitis (eczema), vitiligo, or alopecia areata (a co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06804811 · Incyte Corporation Phase 3 · 14 countries Recruiting
Recruiting Phase 3 Est. completion 30 April 2027
🇦🇷 AR🇦🇹 AT🇧🇪 BE🇧🇬 BG🇩🇰 DK🇫🇷 FR🇩🇪 DE🇭🇺 HU +6 more

**Who might be able to join this trial:** - Children aged 6 to under 12 years old at the time of signing the consent form - Children diagnosed with a specific type of vitiligo called "nonsegmental vitiligo," affecting at least 0.5% of the face area and at least 3% of body areas other than the face - The total vitiligo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06900777 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - Children between 4 and 12 years old who have been diagnosed with a fast-spreading type of vitiligo (called non-segmental vitiligo) that has been getting worse in the past 6 weeks - Children whose vitiligo affects between 1% and 50% of their total body skin - Children whose pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06991972 · Khyber Teaching Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 August 2025
🇵🇰 PK

**Who might be able to join this trial:** - Both men and women are welcome to participate - You must be between 15 and 60 years old - You must have had vitiligo (a skin condition causing loss of skin colour) for more than 1 year **Who may not be able to join:** - People who tend to develop raised or thickened scars (s...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07047612 · Beijing InnoCare Pharma Tech Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2029
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 75 years old (for the Phase II part), or between 12 and 75 years old and weigh at least 40 kg (for the Phase III part) - You have been diagnosed with a specific type of vitiligo called "non-segmental vitiligo" for at least 3 months - Your vitiligo covers at...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07105254 · Derm Texas, PLLC Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 May 2026
🇺🇸 US

**Who might be able to join this trial:** - Children and teenagers aged 2 years old up to (but not including) 18 years old - A parent or legal guardian must give consent for the child to participate, and older children should also agree to join if required by local rules - The child has been diagnosed with a specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07108283 · Takeda Phase 2 · 9 countries Recruiting
Recruiting Phase 2 Est. completion 12 October 2027
🇨🇦 CA🇨🇳 CN🇫🇷 FR🇮🇹 IT🇯🇵 JP🇲🇽 MX🇵🇱 PL🇪🇸 ES +1 more

**Who might be able to join this trial:** - People who are willing and able to follow all trial procedures and requirements, including using digital tools and apps, in the opinion of the trial doctor. - People who have signed a written consent form and any required privacy documents before any trial procedures begin....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07136467 · AbbVie Not Applicable · 18 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇦🇷 AR🇨🇦 CA🇨🇴 CO🇨🇿 CZ🇪🇪 EE🇫🇷 FR🇩🇪 DE🇬🇷 GR +10 more

Who might be able to join this trial: - You have been officially diagnosed by a doctor with one of the following skin conditions: non-segmental vitiligo (a condition causing patches of skin to lose colour), moderate to severe alopecia areata (a condition causing significant hair loss), or moderate to severe hidradeniti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07152626 · Centre Hospitalier Universitaire de Nice Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older (men and women) diagnosed with non-segmental vitiligo (a specific type of vitiligo that does not follow nerve patterns on the body) - People whose vitiligo affects between 4% and 60% of their total body surface area (not counting the palms, soles of the fe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07153666 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

Who might be able to join this trial: - You are 12 years of age or older, of any gender - You have signed the official consent form agreeing to take part in the study - You have been diagnosed by a doctor with non-segmental vitiligo (a type of vitiligo that affects both sides of the body in a scattered pattern) - The w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07172347 · Jiangsu vcare pharmaceutical technology co., LTD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You understand what the trial involves, agree to take part by signing a consent form, and are willing and able to follow the study plan - You are between 18 and 70 years old (inclusive), of any gender **Who may not be able to join:** - You are pregnant, breastfeeding, or pla...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07187882 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with vitiligo, confirmed using the 2021 Vitiligo Diagnosis and Treatment Consensus guidelines - Your vitiligo has been stable (not spreading) — for at least 6 months if you have segmental or unclassified vitiligo, or at least 1 year if you have non-seg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07223229 · Elixiron Immunotherapeutics (Hong Kong) Ltd. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - You are able to read, understand, and sign a consent form agreeing to take part in the study. - You are a man or woman between 18 and 65 years old at the time of signing consent. - Your body weight is at least 40 kg (about 88 lbs) and your body mass index (a measure of weigh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07250997 · Szeged University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇭🇺 HU

**Who might be able to join this trial:** - You understand what the study involves and have agreed to take part by signing a consent form - You have a skin condition that is expected to respond well to a targeted ultraviolet B (UVB) light treatment **Who may not be able to join:** - You are under 18 years of age - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07251595 · Jiangsu HengRui Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You must agree to and sign a consent form before the trial begins. - You must be between 18 and 75 years old (inclusive) on the day you sign the consent form — both men and women may apply. - You and your partner must agree not to try to have children during the study and for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07267273 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇪🇬 EG

**Who might be able to join this trial:** - You have been diagnosed with vitiligo (a skin condition that causes loss of skin color in patches) - You are in good physical and mental health - You are able to understand and follow the requirements of the study - You are willing and able to give your consent to take part -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07357870 · CAGE Bio Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 60 years old and have been diagnosed with a type of vitiligo (called non-segmental vitiligo) on your face or neck - You have 1 to 3 vitiligo patches on your face and/or neck, with a combined size between 6 cm² and 40 cm², where at least 75% of the skin...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07398807 · Combined Military Hospital (CMH) institute of Medical Sciences Bahawal... Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 February 2026
🇵🇰 PK

**Who might be able to join this trial:** - You are willing to take part in the study. - You are between 5 and 70 years old. - Your vitiligo affects 10% or less of your body's skin surface area. **Who may not be able to join:** - You are currently using or have previously used any treatments for vitiligo. - You are pr...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07437560 · Hudson Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are an adult between 18 and 65 years old and are able to give your own consent to participate. - You have been diagnosed with nonsegmental vitiligo (a common form where patches appear in a scattered pattern) that has been stable — meaning no new patches and no existing p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07533019 · Eli Lilly and Company Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇧🇪 BE🇨🇦 CA🇨🇳 CN🇵🇱 PL🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of vitiligo called "non-segmental vitiligo" for at least 3 months - The vitiligo affects between 4% and 60% of your body's skin surface (not counting the palms of your hands, soles of your feet, or the tops of your feet) - At leas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07554222 · Innovent Biologics (Suzhou) Co. Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: **Part 1 – Healthy volunteers:** - You are able to understand and agree to the study by signing a consent form - You are between 18 and 45 years old (male or female) - You weigh between 50 and 120 kg and have a BMI between 17.0 and 28.0 **Part 2 – Vitiligo group:** - You are a ma...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07595705 · Cairo University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇪🇬 EG

**Who might be able to join this trial:** - You have some visible dark (brown to black) spots, patches, or widespread darkening of the gums (based on a specific gum pigmentation scoring system used by dentists) - You are 18 years of age or older - You are in generally good overall health with no systemic (whole-body) i...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07625891 · InventisBio Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form and follow the study's procedures - People aged 18 to 65 years old, of any gender - People who have been diagnosed with non-segmental vitiligo (a type of vitiligo that appears on both sides of the body in a scattered pattern) - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07677826 · Al-Azhar University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are generally healthy (no serious health conditions) and are between 18 and 45 years old, of any gender - You have natural dark coloring on the gums on both sides of your upper or lower front teeth, rated as a moderate to heavy level of pigmentation (confirm with trial si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07712523 · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to communicate clearly with the research team, understand what the trial involves including its risks, and are willing to follow all study requirements and sign a consent form before anything begins. - People who are aged 18 to 65 years old at the time of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Vitiligo. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Vitiligo Association of Australia is the national body for people living with vitiligo.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.